Qiagen N.V. (QGEN)
Market Cap | 10.13B |
Revenue (ttm) | 2.00B |
Net Income (ttm) | 93.68M |
Shares Out | 216.56M |
EPS (ttm) | 0.42 |
PE Ratio | 111.20 |
Forward PE | 19.78 |
Dividend | $1.32 (2.82%) |
Ex-Dividend Date | Jan 29, 2025 |
Volume | 2,124,580 |
Open | 46.60 |
Previous Close | 46.55 |
Day's Range | 46.37 - 46.83 |
52-Week Range | 37.63 - 47.93 |
Beta | 0.67 |
Analysts | Buy |
Price Target | 49.51 (+5.88%) |
Earnings Date | Jul 30, 2025 |
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]
Financial Performance
In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $49.51, which is an increase of 5.88% from the latest price.
News

Qiagen and Gencurix Enter Clinical Diagnostics Partnership
The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assa...

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Sta...

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partner...

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic,...

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of ...

Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential
QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panel...

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox,...

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Berna...

QIAGEN announces plans for transition in leadership of Supervisory Board
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to ...

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today confirmed strong Q1 2025 results in line with the preliminary announcement and ...

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual c...

Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPC...

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its po...

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments du...

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, M...

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earni...

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria re...

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statement...

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared...

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringemen...

Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's f...

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
VENLO, The Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne, Australia, de...